NCT02576444
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PTEN, PI3K, AKT, ARID1A, TP53, KRAS, ARID1A, ATM, BRCA+, CDK, IDH, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have one of the following mutations: TP53, KRAS, TORC1/2, TSC1/2, LKB1, PTEN-deficient, PIK3CA, AKT, ARID1A and/or aberrations leading to disregulation of the PI3k/AKT pathway
Exclusions: Patients with known germline BRCA mutations; patients with active or untreated brain metastases
https://ClinicalTrials.gov/show/NCT02576444